相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study
Rieke Alten et al.
CLINICAL RHEUMATOLOGY (2022)
Treat-to-Target Approach in Rheumatoid Arthritis: A Quality Improvement Trial
Sonali P. Desai et al.
ARTHRITIS CARE & RESEARCH (2021)
Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study
Sei Muraoka et al.
RHEUMATOLOGY AND THERAPY (2021)
The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies
Joel M. Kremer et al.
JOURNAL OF RHEUMATOLOGY (2021)
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Liana Fraenkel et al.
ARTHRITIS CARE & RESEARCH (2021)
Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study
Ernest Choy et al.
BMC RHEUMATOLOGY (2021)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production
Hisakata Yamada et al.
IMMUNOLOGICAL MEDICINE (2020)
Treat to target strategy in early rheumatoid arthritis versus routine care - A comparative clinical practice study
Gina Hetland Brinkmann et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Abatacept for the treatment of rheumatoid arthritis
Manuel Pombo-Suarez et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
Challenges in Implementing Treat-to-Target Strategies in Rheumatology
Julia A. Ford et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2019)
Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
Ruediger B. Mueller et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017
Saeid Safiri et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Physician Adherence to Treat-to-Target and Practice Guidelines in Rheumatoid Arthritis
Bogdan Batko et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Rheumatoid Arthritis
Jeffrey A. Sparks
ANNALS OF INTERNAL MEDICINE (2019)
Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice
Niels W. Boone et al.
RMD OPEN (2019)
Treat-to-target concept implementation for evaluating rheumatoid arthritis patients in daily practice
Tal Gazitt et al.
EUROPEAN JOURNAL OF RHEUMATOLOGY (2019)
Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial
Mark C. Genovese et al.
JOURNAL OF RHEUMATOLOGY (2018)
Implementation of Treat-to-Target for Rheumatoid Arthritis in the US: Analysis of Baseline Data From a Randomized Controlled Trial
Zhi Yu et al.
ARTHRITIS CARE & RESEARCH (2018)
Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice
Peter C. Taylor et al.
PATIENT PREFERENCE AND ADHERENCE (2018)
The extra-articular impacts of rheumatoid arthritis: moving towards holistic care
I. C. Scott et al.
BMC RHEUMATOLOGY (2018)
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update
Michaela A. Stoffer et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
Roy Fleischmann et al.
ARTHRITIS CARE & RESEARCH (2016)
Patient Reported Outcomes in Rheumatoid Arthritis Clinical Trials
Ana-Maria Orbai et al.
CURRENT RHEUMATOLOGY REPORTS (2015)
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry
Marloes Vermeer et al.
BMC MUSCULOSKELETAL DISORDERS (2013)
Mortality in rheumatoid arthritis over the last fifty years: Systematic review and meta-analysis
Sabrina Dadoun et al.
JOINT BONE SPINE (2013)
Treating to a Target in Established Active Rheumatoid Arthritis Patients Receiving a Tumor Necrosis Factor Inhibitor: Results From a Real-World Cluster-Randomized Adalimumab Trial
Janet E. Pope et al.
ARTHRITIS CARE & RESEARCH (2013)
Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs
Vivian P. Bykerk et al.
JOURNAL OF RHEUMATOLOGY (2012)
Treating Rheumatoid Arthritis to Target: A Canadian Physician Survey
Boulos Haraoui et al.
JOURNAL OF RHEUMATOLOGY (2012)
Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction
Daniel Aletaha et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Assessment of control of rheumatoid arthritis disease activity
Karen I. Salomon-Escoto et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2011)
Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome
Lydia G. Schipper et al.
RHEUMATOLOGY (2010)
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
G. Wells et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
RAPID3, an Index to Assess and Monitor Patients with Rheumatoid Arthritis, Without Formal Joint Counts: Similar Results to DAS28 and CDAI in Clinical Trials and Clinical Care
Theodore Pincus et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2009)
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
M. Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Remission and active disease in rheumatoid arthritis - Defining criteria for disease activity states
D Aletaha et al.
ARTHRITIS AND RHEUMATISM (2005)
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
D Aletaha et al.
ARTHRITIS RESEARCH & THERAPY (2005)
A simplified disease activity index for rheumatoid arthritis for use in clinical practice
JS Smolen et al.
RHEUMATOLOGY (2003)
分享论文
